Robert J. Bitterman, Chairman, President & CEO of Phio Pharmaceuticals Corp. (NASDAQ:PHIO), has executed a recent transaction involving the acquisition of company equity. On June 26, 2026, Mr. Bitterman purchased 10,000 shares of common stock at a price of $0.99 per share, totaling $9,900. Following this transaction, his direct ownership in Phio Pharmaceuticals Corp. stands at 421,421 shares. This figure includes shares of common stock underlying unvested restricted stock units.
The insider purchase comes as the stock trades at $0.98, near its 52-week low of $0.81. According to InvestingPro analysis, PHIO appears undervalued with a Fair Value of $1.22. The company maintains a FAIR financial health rating, though InvestingPro Tips highlight that the stock has declined 55% over the past year. Investors seeking deeper insights can access 12 additional ProTips and comprehensive metrics on the platform.
In other recent news, Phio Pharmaceuticals Corp. has announced the commencement of commercial-scale cGMP production of its drug substance, PH-762. The production is taking place at Nitto Denko Avecia, Inc. This marks the first commercial-scale batch of PH-762, which is a significant step for the company. The newly produced supply is intended to support an upcoming clinical trial in the next phase of the drug’s development. These developments reflect Phio Pharmaceuticals’ ongoing efforts to advance its pipeline. The company has not released further details regarding the timeline or specifics of the upcoming trial.
The intersection of insider activity and clinical milestones provides a lens into the current operational phase of Phio Pharmaceuticals. The executive acquisition occurs alongside a period of market consolidation for the stock, which has experienced a 55% decline over the past year. The recent purchase of 10,000 shares at $0.99 per share suggests confidence in the company's trajectory, particularly as it prepares for the next phase of its drug development.
Phio Pharmaceuticals is advancing its pipeline with the commencement of commercial-scale production of PH-762 at Nitto Denko Avecia, Inc. This milestone marks the first commercial-scale batch of the drug substance, which will support an upcoming clinical trial. The company's financial health is rated as FAIR, and the stock currently trades near its 52-week low of $0.81, with a current price of $0.98. Analysts suggest the stock may be undervalued, with a Fair Value estimate of $1.22.
Key Points:
- Robert J. Bitterman acquired 10,000 shares of PHIO on June 26, 2026, at $0.99 per share, bringing his total direct ownership to 421,421 shares.
- Phio Pharmaceuticals has commenced commercial-scale cGMP production of PH-762 at Nitto Denko Avecia, Inc., marking a significant pipeline milestone.
- The stock trades near its 52-week low of $0.81, with a current price of $0.98, and has declined 55% over the past year.
Risks and Uncertainties:
- Phio Pharmaceuticals has not released further details regarding the timeline or specifics of the upcoming clinical trial for PH-762.
- The stock has declined 55% over the past year, indicating potential market volatility and investor sentiment challenges.
- The company's financial health is rated as FAIR, suggesting areas for potential financial scrutiny or improvement.
The biotech sector faces ongoing challenges in drug development timelines and market valuation. Phio Pharmaceuticals' progress with PH-762 and insider buying activity provide insights into the company's strategic direction. The upcoming clinical trial will be a critical determinant of the drug's future potential and the company's market position.